Publications & Insights

Show
In
Published

Narrative Matters ‘How Much Does Zozo Weigh Today?’

March 2010

Lewin Contact: Anjali Jain

Expertise Area: Chronic Disease / Cost of Illness

Temptations In Cyberspace: New Battlefields In Childhood Obesity

March 2010

Lewin Contact: Anjali Jain

Expertise Area: Chronic Disease / Cost of Illness

Economic Value of Self-Care Programs

June 2009

Presentation to Capitol Hill Briefing with NCOA 19 June 2009
Lewin Contact: Lisa Alecxih

Consumers in Control: Cost-Effective Chronic Care Strategies for Health Reform
Friday, June 19, 2009
9:30-11:00 am

Lisa Alecxih, Vice President of the Lewin Group, spoke today at a briefing on Capitol Hill sponsored by the not-for-profit National Council on Aging (NCOA), along with other leading health care experts.  The briefing discussed the results of NCOA's national survey of adults with multiple chronic health conditions.  The Capitol Hill briefing highlighted the day-to-day challenges Americans face in managing their chronic conditions in a fragmented health system, and showcased models that are helping consumers regain control of their health.

Expertise Area: Chronic Disease / Cost of Illness, Health Reform

Distinguishing the Economic Costs Associated with Type 1 and Type 2 Diabetes

April 2009

Novo Nordisk
Lewin contact: Tim Dall

For Novo Nordisk, The Lewin Group estimated the economic costs of diagnosed type 1 (T1DM) and type 2 (T2DM) diabetes mellitus in the United States in 2007. Lewin analyzed medical claims  to estimate the proportion of diagnosed diabetes cases and excess medical costs by diabetes type. Indirect costs associated with T1DM and T2DM were estimated by using findings from the literature on diagnosed diabetes, as well as differences in health per case of T1DM and T2DM. This study builds on the Cost of Diabetes Model developed by Lewin for the American Diabetes Association to estimate the economic burden of diagnosed diabetes. The study is published in the journal Population Health Management.

Client Area: Pharma / Bio / Device
Expertise Area: Chronic Disease / Cost of Illness

The Economic Costs of Undiagnosed Diabetes

April 2009

Novo Nordisk
Lewin contact: Tim Dall

For Novo Nordisk, The Lewin Group conducted a study to estimate the national economic costs associated with undiagnosed diabetes mellitus (UDM). This study builds on previous work on the national costs associated with diagnosed diabetes mellitus. Lewin used a Cost of Diabetes Model that combines data from multiple sources to estimate the national prevalence of UDM in 2007; to quantify differences in health care use patterns for a proxy for the population with UDM compared to a population with no history of diabetes; to estimate the proportion of national health care use and expenditures associated with UDM; and to estimate the loss in national productivity.  The study is published in the journal Population Health Management.

Client Area: Pharma / Bio / Device
Expertise Area: Chronic Disease / Cost of Illness

The Impact of Improved Colorectal Cancer Screening on Adequacy of Future Supply of Gastroenterologists

January 2009

Olympus America, Inc.
Lewin contact: Tim Dall

The purpose of this study is to assess the future adequacy of gastroenterologist supply to help ensure the nation’s ability to provide colonoscopy services. Using two simulation models—the National Colorectal Screening Model and the Physician Supply and Demand Model—the report authors provide evidence-based extrapolations of the impact of changes in CRC screening rates, trends in screening modality, and other trends in gastroenterologist supply and demand determinants on the future adequacy of gastroenterologist supply.

Client Area: Pharma / Bio / Device
Expertise Area: Chronic Disease / Cost of Illness

The Economic Costs of Diabetes in the U.S. in 2007

March 2008

American Diabetes Association
Lewin contact: Tim Dall

Diabetes mellitus is the fifth leading cause of death in the United States. Diabetes also contributes to higher rates of  morbidity – people with diabetes are at higher risk for heart disease, blindness, kidney failure, extremity amputations, and other chronic conditions. The American Diabetes Association (ADA) hired The Lewin Group to study the economic toll of diabetes. As an update to our 2003 study, The Lewin Group estimated the national economic burden of diabetes at $174 billion in 2007. This consists of approximately $116 billion in additional health care expenditures attributed to diabetes, and $58 billion in lost productivity from absenteeism, reduced productivity, permanent disability, and premature mortality.  The study appears in the March 2008 issue of the journal, Diabetes Care.

Client Area: Associations
Expertise Area: Chronic Disease / Cost of Illness

Prevalence and Treatment Patterns of Pelvic Health Disorders Among U.S. Women

June 2007

National Women's Resource Center

The National Women's Health Resource Center (NWHRC) has released a new report by The Lewin Group. The report, Prevalence and Treatment Patterns of Pelvic Health Disorders Among United States Women, examines four pelvic health conditions–menorrhagia, uterine fibroids, stress urinary incontinence (SUI) and pelvic organ prolapse–that commonly affect women and, in particular, Baby Boomer women born between 1946 and 1964. The report addresses five key issues regarding each of the respective disorders: What is the prevalence among women in the United States, and how does prevalence differ by age and other demographic variables? How do these disorders affect women, and, in particular Baby Boomers in the United States? To what extent is the magnitude and severity of these disorders properly recognized and understood by public health practitioners, researchers and policymakers? Does a treatment gap exist? Do current treatment patterns reflect the most effective and appropriate standards of practice?

Some of the report’s key findings include: At least one-third of all women in the United States will be treated for one or more pelvic health disorders by the age of 60. The Baby Boomer generation is currently in the phase of life with the highest rate of onset for pelvic health disorders. Pelvic health disorders have a substantial impact on women’s health and quality of life. Women’s reluctance to consult their physicians about symptoms associated with pelvic health disordrs results in under- and/or misdiagnosis, further complicating the treatment and overall understanding of the impact of these disorders. Current patterns of care indicate that clinically recommended and effective treatments generally are employed for each disorder. However, some clinicians and researchers are concerned about the common use of hysterectomies for menorrhagia and uterine fibroids, as well as the rate of anterior repairs used to treat SUI.

Expertise Area: Chronic Disease / Cost of Illness

The Prevalence and Cost of Select Chronic Diseases

March 2007

Pharmaceutical Research and Manufacturers of America (PhRMA)

This report explores the prevalence and economic impact of various chronic diseases in the states of South Carolina, Iowa, and New Hampshire. The chronic diseases covered include cardiovascular disease, diabetes, cancer, depression, and asthma.

Client Area: Associations
Expertise Area: Chronic Disease / Cost of Illness

Chronic Health Conditions & the New Medicare Part D Benefit: Savings on Frequently Used Medications: Executive Summary

April 2006

Healthcare Leadership Council
Lewin contact: Lisa Chimento

This study, commissioned by the Healthcare Leadership Council, analyzes savings available to Medicare beneficiaries with common chronic conditions who enroll in a Prescription Drug Plan (PDP). The five chronic conditions studied are arthritis, diabetes, hypertension, osteoporosis and respiratory illness. 84 percent of Medicare beneficiaries report having at least one of these most common diagnoses. Lewin finds that, nationwide, beneficiaries can save 43 to 58 percent by enrolling in one of the 5 PDPs with the lowest costs. The executive summary presents information at a national level by chronic condition. Available in separate files are state level findings for Alabama-Kentucky, Louisiana-North Dakota, and Ohio-Wyoming. Also available in separate files are the appendices which provide additional detailed data for Alabama-Kentucky, Louisiana-North Dakota, and Ohio-Wyoming.

Client Area: Associations
Expertise Area: Chronic Disease / Cost of Illness, Medicare

The Burden of Skin Diseases: 2005

April 2005

Society for Investigative Dermatology; American Academy of Dermatology Association
Lewin contact: Clifford Goodman

Skin diseases have a broad and burdensome impact on the health and well-being of Americans, and account for substantial health care costs to the nation. Skin disease is one of the top 15 groups of medical conditions for which prevalence and health care spending grew the most between 1987 and 2000, exceeding spending rate increases for diabetes,cerebrovascular disease, and cancer. The purpose of this study, sponsored by the Society for Investigative Dermatology and the American Academy of Dermatology Association, was to estimate the prevalence, annual economic burden, and quality of life implications of a major group of skin diseases.

Client Area: Associations
Expertise Area: Chronic Disease / Cost of Illness

Fee Reconciliation Process under the Texas Medicaid Disease Management Program

January 2005

Texas Health and Human Services Commission
Lewin contact: Joel Menges

Lewin assisted Texas' Health and Human Services Commission (HHSC – the state's Medicaid agency) in designing the detailed mechanisms by which cost performance would be measured. The contractor's administrative fees are 80% at risk for cost performance, and 20% at risk for quality performance. Lewin evaluated vendors' price bids and then worked extensively with HHSC to develop and negotiate the measurement criteria with the selected contractor. Lewin has also developed appropriate algorithms for identifying patients in each targeted disease category, specifying situations where persons will be excluded from the program, and designing and negotiating all aspects of HHSC's financial relationship with its disease management contractor.

Client Area: State and Local Governments
Expertise Area: Chronic Disease / Cost of Illness, Medicaid and CHIP

Saving Lives, Saving Money: Dividends for Americans from Investing in Alzheimer Research

June 2004

Alzheimer's Association
Lewin contact: Lisa Alecxih

To measure the cost benefit of potential Alzheimer research on Medicare and Medicaid spending and disease prevalence, the Alzheimer's Association commissioned The Lewin Group to conduct an analysis of potential savings the U.S. could realize with major breakthroughs in Alzheimer research. The report of this analysis, entitled Saving Lives, Saving Money: Dividends for Americans from Investing in Alzheimer Research, was released on June 23, 2004. The study assumes that by 2010, researchers will find a way to delay the onset of Alzheimer's disease just as scientists have been able to delay the onset of congestive heart failure, and a way to slow the progression of Alzheimer's just as they have slowed the progression of Parkinson's disease.

Client Area: Associations
Expertise Area: Chronic Disease / Cost of Illness

The Economic Impact of Chronic Fatigue Syndrome

June 2004

Centers for Disease Control and Prevention

For the Centers for Disease Control and Prevention, Lewin and Scientific Research Associates, Inc. developed estimates of lost labor market and lost household productivity at the societal and individual levels including sensitivity analysis around the key factors affecting the estimates for Chronic Fatigue Syndrome (CFS). Study objective included identification of data and/or evidence gaps that hinder thorough and sophisticated economic impact analysis of CFS and to provide recommendations for future analysis of CFS.

Client Area: Federal Government
Expertise Area: Chronic Disease / Cost of Illness

Economic Costs of Diabetes in the U.S. in 2002

March 2003

American Diabetes Association
Lewin contact: Tim Dall

For the American Diabetes Association, The Lewin Group conducted a study on the national cost of diabetes. We estimated that diabetes cost the nation approximately $132 billion in 2002, with direct medical expenditures totaling $91.2 billion and indirect expenditures (resulting from lost work days, restricted activity days, mortality and permanent disability) totaling $39.8 billion.

Client Area: Associations
Expertise Area: Chronic Disease / Cost of Illness

Cost Effectiveness and Cost Benefit Analysis of Substance Abuse Treatment: A Literature Review

June 2002

DHHS, Center for Substance Abuse Treatment

This literature review summarizes the major findings from books, published articles, research and evaluation studies, and government documents (including "Web" publications) published since 1980, which focus on the cost effectiveness and cost benefits of substance abuse treatment. Cost effectiveness and cost benefit studies play an important role in evaluating existing and alternative substance abuse approaches and in assessing new treatment methods. Evaluating the outcomes and costs of treatment is necessary in order to determine how to more efficiently allocate scarce resources. This document is intended to assist policymakers, researchers/evaluators, and treatment providers interested in this field to identify and acquire evidence-based information specific to their interests. This review also explores trends and areas where there are gaps in the literature.

Client Area: Federal Government
Expertise Area: Chronic Disease / Cost of Illness, Mental Health and Substance Abuse

Cost Effectiveness and Cost Benefit Analysis of Substance Abuse Treatment: An Annotated Bibliography

June 2002

DHHS, Center for Substance Abuse Treatment

This bibliography lists books, published articles and research/evaluation studies, and government documents (including "Web" publications) published since 1980 that focus on the costs of substance abuse treatment, methods for estimating the costs of treatment, and studies of the cost effectiveness and cost benefits of substance abuse treatment. This document also identifies trends and areas where there are gaps in the literature. A companion document, Cost Effectiveness and Cost Benefit Analysis of Substance Abuse Treatment: A Literature Review, synthesizes the major findings from the reports and studies focusing on the cost effectiveness and cost benefits of substance abuse treatment identified in this bibliography.

Client Area: Federal Government
Expertise Area: Chronic Disease / Cost of Illness, Mental Health and Substance Abuse

The Burden of Gastrointestinal Diseases

May 2001

American Gastroenterological Association
Lewin contact: Clifford Goodman

This study, conducted by The Lewin Group for the American Gastroenterological Association, analyzed major national and local databases to assess prevalence and cost of 17 digestive conditions: gastroesophageal reflux disease (GERD), gallbladder disease, irritable bowel syndrome (IBS), peptic ulcers, chronic liver disease and cirrhosis, chronic hepatitis C**, chronic diarrhea, diverticular disease, diseases of pancreas, Barrett's esophagus, ulcerative colitis, colorectal cancer, Crohn's disease, pancreatic cancer, liver cancer, foodborne illness and non-foodborne gastroenteritis. An article based on the study was published in the May 2002 issue (Volume 122 No 5) of the journal Gastroenterology.

Client Area: Associations
Expertise Area: Chronic Disease / Cost of Illness

Costs of Obesity

December 2000

American Obesity Association

This study estimated the direct costs of obesity to healthcare and found that the cost of all treatments for obese adults (defined as having a body mass index greater than 30) would be $238 billion in 1999, which includes $102 billion for 15 diseases that the project team specifically identified as associated co-morbidities. The study also found that approximately 75% of the direct costs were attributed to five diseases: Type II Diabetes, Heart Disease, Stroke, Hypertension, and Arthritis. The American Obesity Association sponsored the study, and the results were presented at the first annual Obesity Conference that took place in Washington, DC on September 15th, 1999. The study presentation was revised September 13, 2000 to include slides on the cost of obesity in children

Client Area: Associations
Expertise Area: Chronic Disease / Cost of Illness

The Economic Cost of Mental Illness, 1992

May 2000

National Institute on Drug Abuse

The aim of this study is to identify and quantify the adverse impacts of mental illness and sum together the magnitude of these consequences using economic values—in dollars. This report estimates the direct economic impact of mental illness for 1992 and for 1995.

Client Area: Federal Government
Expertise Area: Chronic Disease / Cost of Illness, Mental Health and Substance Abuse

Economic Cost of Alcohol and Drug Abuse in the United States, 1992

May 1998

National Insitute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism

The Lewin Group developed estimates of the costs of drug and alcohol abuse in 1992 for The National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). The study estimated the economic cost to society from alcohol and drug abuse at $246 billion in 1992. Alcohol abuse and alcoholism cost an estimated $148 billion, while drug abuse and dependence cost an estimated $98 billion.

Client Area: Federal Government
Expertise Area: Chronic Disease / Cost of Illness, Mental Health and Substance Abuse

The Cost of Covering Medical Nutrition Therapy under Medicare: 1998 through 2004

April 1997

American Dietetic Association

Analysis of data from a Northwestern HMO shows that the use of dietition services under Medicare Part B as specified in the Medical Nutrition Therapy Act of 1995 can reduce inpatient and physician service use for patients with diabetes and/or cardiovascular disease. Utilization savings appeared within the first calendar quarter and increased over time. Authors found also that the program could produce net savings to Medicare over the period analyzed (1998 to 2000) if coverage is limited to those with diseases demonstrated to show savings.

Client Area: Associations
Expertise Area: Chronic Disease / Cost of Illness, Medicare

Showing 22 item(s)

Contact Us
  703.269.5500
M–-F, 8:30–5:30 Eastern Time

  Email The Lewin Group

“It’s a pleasure to work with Lewin. They provide us with quality products and are very open to feedback. We have an excellent working relationship and are confident in their ability to provide exceptional service.”  FEDERAL AGENCY